References
- Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 370(9583), 263–271 (2007).
- Laws P, Barton A, Warren RB. Psoriatic arthritis – what the dermatologist needs to know. J. Eur. Acad. Dermatol. Venereol. 24(11), 1270–1277 (2010).
- Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm. Venereol. 90(2), 147–151 (2010).
- Ludvigsson JF, Lindelöf B, Zingone F, Ciacci C. Psoriasis in a nationwide cohort study of patients with celiac disease. J. Invest. Dermatol. 131(10), 2010–2016 (2011).
- Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ. Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization. Am. J. Gastroenterol. 102(7), 1429–1435 (2007).
- Hébert HL, Ali FR, Bowes J, Griffiths CE, Barton A, Warren RB. Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br. J. Dermatol. 166(3), 474–482 (2012).
- Tsoi LC, Spain SL, Knight J et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat. Genet. 44(12), 1341–1348 (2012).
- Warren RB, Smith RL, Flynn E et al.; UKRAG Consortium. A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. Br. J. Dermatol. 164(3), 660–664 (2011).
- Ali FR, Barton A, Smith RL et al. An investigation of rheumatoid arthritis loci in patients with early-onset psoriasis validates association of the REL gene. Br. J. Dermatol. doi:10.1111/bjd.12106 (2012) (Epub ahead of print).
- Bowes J, Ho P, Flynn E et al. Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. Ann. Rheum. Dis. 71(8), 1350–1354 (2012).
- Strange A, Capon F, Spencer CC et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat. Genet., 42(11), 985–990 (2010).
- Gregersen PK, Amos CI, Lee AT et al. REL, encoding a member of the NF-κB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat. Genet. 41(7), 820–823 (2009).
- Barrett JC, Hansoul S, Nicolae DL et al.; NIDDK IBD Genetics Consortium; Belgian-French IBD Consortium; Wellcome Trust Case Control Consortium. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat. Genet. 40(8), 955–962 (2008).
- Hinks A, Barton A, John S et al. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum. 52(6), 1694–1699 (2005).
- Criswell LA, Pfeiffer KA, Lum RF et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am. J. Hum. Genet. 76(4), 561–571 (2005).
- Smith RL, Warren RB, Eyre S et al. Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. Br. J. Dermatol. 158(5), 962–968 (2008).
- Samarasekera E, Sawyer L, Parnham J, Smith CH; on behalf of the Guideline Development Group. Assessment and management of psoriasis: summary of NICE guidance. BMJ 345, e6712 (2012).
- Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin. Exp. Rheumatol. 27(3), 469–474 (2009).
- Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366(13), 1181–1189 (2012).
- Leonardi C, Matheson R, Zachariae C et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366(13), 1190–1199 (2012).
- Ryan C, Menter A, Warren RB. The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. Mol. Diagn. Ther. 14(2), 81–93 (2010).
- Burden AD, Warren RB, Kleyn CE et al.; BADBIR Study Group. The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectives. Br. J. Dermatol. 166(3), 545–554 (2012).